Clinical Trials Directory

Trials / Completed

CompletedNCT04354038

Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations

Host and Bacterial Mechanisms in Recovering FEV1 After Pulmonary Exacerbations in Patients With Cystic Fibrosis

Status
Completed
Phase
Study type
Observational
Enrollment
29 (actual)
Sponsor
National Jewish Health · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cystic fibrosis pulmonary exacerbations (CF PEx) vary greatly in their severity, their pathogens, and their treatment responses. A failure to return to baseline lung function after treatment may be due to persistent infection or chronic inflammation or both. This constant infection and inflammation are believed to be tightly connected, making it difficult to know the exact reason why some patients fail to respond to treatment. The purpose of this study is to evaluate both infection and inflammation during CF PEx to allow for more personalized approaches to improve lung function responses and better CF PEx outcomes. Subjects will be asked to be in the study if they have CF, are 18 years of age or older, and are starting on IV antibiotics due to worsening lung infection. Subjects will stay in the study for up to 5 years, with visits occurring once a year if hospitalized for a CF PEx. Each visit will have blood, sputum, and urine collected and analyzed for changes in expression of certain genes and proteins. These changes may relate to improvements felt by people living with CF and determine what treatments are most helpful.

Conditions

Timeline

Start date
2020-01-07
Primary completion
2021-09-21
Completion
2023-09-22
First posted
2020-04-21
Last updated
2026-04-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04354038. Inclusion in this directory is not an endorsement.